NCT00783224已完成3 期
Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 351
- 主要终点
- Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks
研究概览
简要总结
This study was conducted to see if mometasone nasal spray is efficaceous for the treatment of perennial allergic rhinitis. Patients will be randomized to active mometasone, placebo mometasone, active fluticasone, or placebo fluticasone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with perennial allergic rhinitis meeting all of the followings.
- •Patients with symptoms of perennial allergic rhinitis, the severity of which is moderate or severer according to the severity grading provided in the "Guidelines for the Management of Allergic Rhinitis in Japan" (partly modified) with the 4-nasal symptom score of 4 or over at informed consent and during the pre-treatment observation period
- •Patients with positive reaction to the eosinophil count in nasal discharge or nasal challenge test in addition to the skin test or specific IgE antibody test
- •Outpatients aged 16 years or over at informed consent
- •Patients in either sex
- •Patients (or their legal representatives in case of patients aged under 20 years) capable of giving written informed consent
- •Patients capable of recording nasal allergy diary every day
排除标准
- •Patients with a complication of tuberculous diseases or lower respiratory tract infections, and those with a complication of otorhinolaryngeal infections(acute upper respiratory tract inflammation, acute laryngopharyngitis, acute tonsillitis, etc.) requiring treatments judged by the investigator (subinvestigator) at the time of enrollment to randomization
- •Patients with a complication of infection or systemic mycosis for which no effective antibiotics are available
- •Patients with a complication of recurrent epistaxis
- •Patients with uncured nasal septal ulcer, operated nose or nasal trauma.
- •Patients with a history of hypersensitivity to steroids and any ingredients of the study drugs
- •Pregnant, lactating or possibly pregnant patients or the patients who themselves or whose partners wish to become pregnant during the study
- •Patients with severe hepatic or renal disorder, heart or blood disease, diabetes mellitus, hypertension, or other serious complication, suffering from problems with systemic condition
- •Patients who have pollens as multiple allergens and the period from 7 days before enrollment to randomization to completion of the treatment period coincides with the period of scattering of relevant pollens
- •Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis
- •Patients with a complication of a nasal disease (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, or septal deviation) which may interfere with efficacy evaluation of the study drugs
- •Patients with a complication of a disease (acute upper respiratory tract inflammation, acute laryngitis or acute tonsillitis, etc.) of severity affecting nasal symptoms within 7 days before enrollment
- •Patients who have previously received MF nasal spray
- •Patients who used FP nasal spray within 28 days before initiation of the pre-treatment observation period (7 days before enrollment to randomization)
- •Patients who have participated in clinical trials of other investigational product(s) within 120 days (4 months) before obtaining informed consent or participating at present
- •Patients in whom prior medication expected to be effective for allergic rhinitis was not drawn long enough before initiation of treatment with the investigational product or the preceding medication cannot be withdrawn
- •Patients who are being treated with specific desensitization therapy or nonspecific allassotherapy or in whom such the therapy was withdrawn within 90 days (3 months) before obtaining informed consent (except for patients receiving the maintenance therapy at present in whom the therapy began more than 180 days (6 months) before obtaining the informed consent)
- •Other patients whom the investigator or the subinvestigator judged to be inappropriate for participation in the present study
研究组 & 干预措施
Mometasone Furoate Placebo (PLAMF)
Placebo Comparator
Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
干预措施: Placebo for MF (Drug)
Fluticasone Propionate Placebo (PLAFP)
Placebo Comparator
Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
干预措施: Placebo for FP (Drug)
Mometasone Furoate (MF)
Experimental
Mometasone furoate nasal spray 200 μg/day(QD)
干预措施: Mometasone (Drug)
Fluticasone Propionate (FP)
Active Comparator
Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
干预措施: Fluticasone (Drug)
结局指标
主要结局
Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks
时间窗: Baseline to 2 weeks of treatment
The nasal symptoms (sneezing attacks, rhinorrhea, nasal congestion and itching) were rated in 4 grades (+++: 3 points, ++: 2 points, +: 1 point, -: 0 point) based on the evaluation criteria for nasal symptoms. Total possible best score is 0 points, total possible worst score is 12 points.
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)Rhinitis, AllergicNCT03855228Organon and Co704
已完成
4 期
Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus SurgerySinusitisNasal PolypsAsthmaNCT02110654First Affiliated Hospital, Sun Yat-Sen University50
进行中（未招募）
1 期
An exploratory study of mometasone furoate nasal spray in patients with moderate-severe persistent allergic rhinitis and intermittent asthma: effects on the quality of life evaluated with the Rhinasthma questionnaire - NDpersistent allergic rhinitis and concomitant intermittent asthmaMedDRA version: 9.1 Level: LLT Classification code 10039085 Term: Rhinitis allergicEUCTR2007-004683-45-ITSCHERING-PLOUGH56
已完成
4 期
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)Seasonal Allergic RhinitisNCT00491504Organon and Co310
Unknown
3 期
Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal SpraysNasal ObstructionSneezingItchingNCT01702103PH&T S.p.A.360